Thus, BET inhibitors which release BRD4 from chromatin downregulate expression of T-ALL genes like MYC and suppress T-ALL cell survival in vitro and in pre-clinical models5,13,19. The gene discussed is BRD4; the disease is acute lymphoblastic leukemia.